Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered the only curative treatment for relapsed or refractory follicular lymphoma (FL), but it has a high treatment-related mortality rate. Only a few reports, however, have described the efficacy of allo-SCT for FL in the Japanese...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2013-10, Vol.98 (4), p.463-471
Main Authors: Ito, Yoshikiyo, Miyamoto, Toshihiro, Kamimura, Tomohiko, Takase, Ken, Henzan, Hideho, Sugio, Yasuo, Kato, Koji, Ohno, Yuju, Eto, Tetsuya, Teshima, Takanori, Akashi, Koichi
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Cause of Death
Clinical outcomes
Female
Follow-Up Studies
Graft Survival
Graft vs Host Disease - etiology
Graft vs Host Disease - prevention & control
Hematologic and hematopoietic diseases
Hematology
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, Follicular - mortality
Lymphoma, Follicular - pathology
Lymphoma, Follicular - therapy
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Recurrence, Local
Oncology
Original Article
Retrospective Studies
Transplantation Conditioning
Transplantation, Homologous
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered the only curative treatment for relapsed or refractory follicular lymphoma (FL), but it has a high treatment-related mortality rate. Only a few reports, however, have described the efficacy of allo-SCT for FL in the Japanese population. We retrospectively analyzed the outcome of allo-SCT in 30 patients with FL. Seventeen (56.7 %) patients were chemorefractory, whereas 13 (43.3 %) were chemosensitive. An estimated 2-year overall survival rate (OS) and relapse rate of all patients was 46.7 and 20.0 %, respectively. There were no significant differences in the estimated 2-year OS rate between patients who received myeloablative conditioning and those who received reduced-intensity conditioning ( P  = 0.98), and among the recipients of related bone marrow (BM)/peripheral blood stem cell, unrelated BM and umbilical cord blood ( P  = 0.20). In patients who were either chemosensitive or chemorefractory at allo-SCT, the 2-year OS rate was 69.2 and 29.4 % ( P  = 0.06). Patients with mild-to-moderate acute GVHD had better 2-year PFS rate compared with patients who had severe acute GVHD ( P  = 0.01), but not better PFS compared with patients who had no acute GVHD ( P  = 0.12). Our results suggest that the graft-versus-lymphoma effects of allo-SCT may provide survival benefits even in patients with chemorefractory FL.
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-013-1430-9